Journal
ANALYTICAL CHEMISTRY
Volume 83, Issue 8, Pages 3205-3210Publisher
AMER CHEMICAL SOC
DOI: 10.1021/ac103213j
Keywords
-
Categories
Funding
- Russian Academy of Sciences
- Russian Foundation of Basic Research [09-04-12130, 09-04-12225, 09-04-00725, 09-03-92500, 07-02-01482, 10-04-13306]
- ICGEB [CRP/RUS08-02]
- Russian Federal program [02.512.11.2329, 02.512.11.2197, 16.512.11.2081, 16.740. 11.0369, 14.740.11.0755]
- Russian Academy of Medical Sciences
Ask authors/readers for more resources
There is strong evidence that the amyloid-P peptide (A beta) plays a crucial role in the pathogenesis of Alzheimer's disease (AD), a lethal neurodegenerative disorder of the elderly. During pathology development, the peptide as well as its various chemically modified isoforms is accumulated the so-called amyloid plaques, which are the pathomorpholo-in specific brain tissues as characteristic proteinaceous deposits, gical mark of AD, although the level of A beta in the blood is the same for healthy individuals and for AD patients. Earlier, it has been shown that isomerization of aspartate 7, the most abundant post translational modification of the A beta peptide, is tightly involved in a set of molecular processes associated with AD progression. Therefore, the isoAsp 7-containing A beta isomer (isoA beta) is assumed to be a potential biomarker of AD that can be identified in the blood. Here, we present an analytical mass spectrometric method for quantitative determination of the ratio of normal and isomerized A beta fragments 1-16 in their binary mixtures, and all analytical capabilities, such as accuracy, detection limits, and sensitivity of the presented method, are determined and thoroughly discussed. On the basis of this method, an analytical approach for quantitative determination of this modification in the blood will be developed in further studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available